Skip to main
PACB
PACB logo

PACB Stock Forecast & Price Target

PACB Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 14%
Buy 29%
Hold 57%
Sell 0%
Strong Sell 0%

Bulls say

Pacific Biosciences of California Inc. demonstrated a notable improvement in gross margins year-over-year, attributed primarily to a higher mix of consumables revenue. The company reported significant utilization of its Revio platform, which reached its highest level since launch, indicating strong demand and successful market penetration. Furthermore, management expressed optimism regarding sequential growth in Vega placements, suggesting potential for continued revenue expansion throughout the year.

Bears say

The outlook for Pacific Biosciences of California Inc is negative primarily due to an anticipated decline in gross margins, projected to be lower in Q2 compared to the 40.4% margin reported in Q1, indicating potential profitability concerns. Additionally, if the company experiences stagnant utilization rates or if demand for new instruments fails to meet expectations, its financial targets for 2026 could be jeopardized, potentially leading to adverse reactions in the stock price. Furthermore, the ongoing demand weakness in the life sciences tools sector, particularly in China, is expected to continue throughout 2023 and into 2024, contributing further to the negative financial outlook.

PACB has been analyzed by 7 analysts, with a consensus rating of Buy. 14% of analysts recommend a Strong Buy, 29% recommend Buy, 57% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Pacific Biosciences of California and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Pacific Biosciences of California (PACB) Forecast

Analysts have given PACB a Buy based on their latest research and market trends.

According to 7 analysts, PACB has a Buy consensus rating as of Oct 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $1.90, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $1.90, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Pacific Biosciences of California (PACB)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.